Category Archives: Uncategorized

“Ending AIDS” will mean filling cracks and chasms of neglect, inequity and exclusion . . . We’re reading about HLM 2016 AIDS

By on .

The United Nations High-Level Meeting on Ending AIDS this week could give the impression by its name alone that, but for a few loose ends, the end of HIV as a global health threat is within grasp. But in numbers alone, with fewer than half the people living with HIV worldwide accessing the antiretroviral treatment […]

World AIDS Day Event: HIV services fail children

By on .

While the Obama administration commemorated World AIDS Day at the White House and celebrated progress in the fight against HIV, global HIV advocates at a Capitol Hill briefing Monday discussed how that progress has left young people and children behind. With more than two million children who need antiretroviral drugs not receiving them, HIV treatment […]

AIDS Vaccine 2012 will highlight scope of promising prevention advances

By on .

With a completed trial in Thailand that offered evidence a vaccine could be developed to protect people from HIV, emerging science identifying antibodies against HIV, and a current trial testing a novel vaccine combination against the virus potentially producing more information in the next year, this is an exciting time to hold a conference, organizers […]

Dr. Fauci on innovative HIV vaccine initiative awards: “There are fundamental questions that remain unanswered”

By on .

Researchers at 14 institutions will explore new approaches to designing a vaccine against HIV with awards that are part of an anticipated four-year, $34.8 million initiative, the National Institute of Allergy and Infectious Diseases announced today. The awards reflect directions suggested by previous research, as well as the need to explore new avenues toward a […]

CDC issues interim guidelines on preexposure antiretroviral use for heterosexual adults

By on .

The Centers for Disease Control and Prevention has released guidelines for clinicians prescribing antiretroviral medicine to prevent acquisition of HIV in heterosexual men and women, saying daily doses of Truvada can be safe and effective in reducing risk of infection. The guidelines, released in the agency’s August 10 Morbidity and Mortality Weekly Report, emphasize that […]

With sex workers and drug users banned from US travel, AIDS 2012 features sessions about them, without them

By on .

Some of the best news for some of those hit hardest by the epidemic came early in AIDS 2012 with Secretary Clinton’s welcoming remarks, when, citing progress in both science and implementation, while emphasizing the impact of the epidemic on sex workers and people who use injecting drugs, she told the audience ” . . […]

CDC economic models show HIV treatment scale-up is cost-effective, can save money over time

By on .

New economic modeling shows that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too. Dr. John Blandford of  the Centers for Disease Control and Prevention’s Center for Global Health and his team of colleagues have found that cost savings from averted negative […]

Sec. Clinton: “Creating an AIDS-free generation has never been a priority of the U.S. government until today…”

By on .

The community responds to Clinton’s momentous speech

The U.S. Secretary of State Hilary Clinton made a bold announcement Tuesday – that an AIDS free generation is possible and the U.S. will be working toward that goal. Aiming to reinvigorate the fight against global AIDS, she emphasized the leadership role the U.S. must play but, as administration folks have reiterated for several months, the U.S. cannot do it alone.

Activists put a spotlight on drug company yet to join AIDS drug patent pool

By on .

College students, people living with AIDS, and community members held a “pool party” outside of Merck’s laboratories in Boston Friday, to speak out about the company’s hesitation to join the Medicines Patent Pool  (MPP) – a two-year-old organization that works with drug companies to create licenses that allow generic drug companies to produce their patented […]

NIAID Closes HIV Prevention Study among Injection Drug Users

By on .

The National Institute of Allergy and Infectious Diseases (NIAID) is set to close out the HPTN 058 study, a Phase III clinical trial that started in 2007 and was tasked with evaluating whether or not administering opiate dependence medication, combined with drug and HIV risk-reduction counseling, can prevent HIV infection and death among opiate-dependent injection […]